Purified a-fetoprotein (AFP), fucosylated AFP mixtures, and 40 sera from patients with AFP-producing hepatocellular carcinoma were analysed by monoclonal enzyme immunoassay (EIA) to distinguish fucosylated and nonfucosylated AFP molecular variants. FUC-AFP-25 was discriminated from FUC-AFP-75 by the EIA using monoclonal antibody 18H4 in the range of total AFP concentrations from 100 to 800 ngjmL. In addition, sera from 40 patients with hepatocellular carcinoma, with AFP concentrations from 100 to 1270 ngjmL and with fucosylated AFP from 0 to 100% by conventional cross immunoaffinoelectrophoresis, were also analysed by the present EIA. A statistically significant correlation was obtained between the data from the present EIA and from the conventional crossed immuno-affinoelectrophoresis in the range of fucosylated AFP more than 20% and the serum concentration of AFP more than 100 ngjmL. These results indicate that the present EIA is useful for clinical detection of hepatocellular carcinoma during the follow-up of patients with chronic liver diseases.
Alpha-fetoprotein (AFP) is one of the most useful carcinofetal proteins.':" It is generally accepted that longitudinal measurements of serum AFP concentrations are important for the diagnosis of hepatocellular carcinoma during the follow-up of patients with chronic liver diseases."? The concentration of serum AFP, however, is often increased to more than 400 ngjmL in patients with benign liver diseases"!" whilst it is sometimes less than 400 ngjmL in patients with hepatocellular carcinorna.U'<" especially in the early stage. Therefore, it is important to develop a method which will distinguish hepatocellular carcinoma from non-neoplastic liver diseases.
Our previous report showed a difference in the binding pattern of AFP with Lens culinaris agglutinin (LCA) between hepatocellular carcinoma and benign liver diseases, using crossed immuno-affinoelectrophoresis. 3. 7. 9 An increase of the LCA-reactive species of AFP in patients with hepatocellular carcinoma was indicated by this method." We also indicated that fucosylation of Correspondence: Y. Suzuki. 121 the sugar chain was the molecular basis for this AFP variation'<':" However, the method with crossed immuno-affinoelectrophoresis requires great skill and is therefore not appropriate for clinical routine work.
In our recent study, purified fucosylated and non-fucosylated AFP were distinguishable by a simpler enzyme immunoassay using monoclonal anti-AFP antibody in the presence of LCA at AFP concentrations from 200 to 1000 ngjmL. 13 The present study describes a clinical application of the simpler method to distinguish fucosylated from non-fucosylated AFP.
MATERIALS AND METHODS
AFP Alpha-fetoprotein from the serum of a patient with hepatocellular carcinoma was purified by affinity chromatography and DEAE-Sephadex chromatography (Pharmacia Fine Chemicals, Uppsa1a, Sweden) as previously described." The fucosylated and non-fucosylated molecular species of AFP were separated by affinity chromatography with LCA-Sepharose 4B (Pharmacia Fine Chemicals)." The AFP mixture, FUC-AFP-25, consisted of 25% fucosylated and 75% non-fucosylated AFP, and FUC-AFP-75 consisted of 75% fucosylated and 25% nonfucosylated AFP in AFP-free normal serum.
Serum samples
Serum samples were obtained from 40 patients with AFP-producing hepatocellular carcinoma, and stored at -20°C until assayed. The concentrations of AFP ranged from \00 ng/ml, to 1270 ng/ml. as determined by an EIA kit (Dainabot Corporation Ltd, Tokyo, Japan). Percentages of fucosylated AFP ranged from 0 to \00% as determined by conventional crossed immuno-affinoelectrophoresis.
Reagents
Lyophilized salt-free LCA (L-5880) was obtained from Sigma Chemical Company (St Louis, Missouri, USA). Beta-D-galactoside galactohydrolase was from Boeringer Mannheim Biochemica (West Germany).
Monoclonal anti-AFP antibody
The monoclonal antibody (McAb) 18H4 was selected, as described previously." The antibody was derived from the hybridomas of P3UI mouse myeloma cells and splenocytes of mice immunised with AFP purified from human fetal cord serum. This monoclonal antibody was purified from ascites fluids by affinity chromatography with Protein A-Sepharose 4B (Pharmacia Fine Chemicals). This McAbl8H4 was of the IgG I subclass.
Polyc1onal anti-AFP antibody Polyclonal anti-AFP antibody (PcAb) was obtained from a rabbit by immunization with purified AFP, and purified using an AFP coupled agarose column as described previously."
PcAlH':oated polystyrene beads Polystyrene beads (6,5 mm in diameter, Mitsui Pharmaceutical Inc, Tokyo, Japan) were coated with l5Jlg/mL of purified PcAb in degassed 50mM Tris-HCI buffer (pH 7'5) containing 150mM NaCI, I mM MgCh, I mM CaCI 2 and 0·02% NaN] (buffer A) at 4°C for 1 week. Postcoating was performed in buffer A containing 3% BSA.
Galactosidase-labelled McAb 18h4 (conjugate 18h4)
Beta-D-galactoside galactohydrolase-labelled McAbl8H4 was prepared by conjugation of reduced l8H4 with p-D-galactosidase using N,N'-o-phenylenedimaleimide, as described. IS Enzyme immunoassay and inhibition with LeA Enzyme immunoassay was carried out with the sandwich method composed of solid phase PcAb and p-D-galactosidase-Iabelled conjugate of McAbI8H4. The polystyrene beads coated with PcAb were incubated at 37°C for 1 h with FUC-AFP-25 or FUC-AFP-75 at various AFP concentrations prepared in AFP-free normal human serum. After washing, the beads were immersed in the conjugate 18H4 solution at 4°C for 1 h. They were then incubated in p-nitrophenyl-p-Dgalactopyranoside (Nakarai Chemicals, Ltd, Kyoto, Japan) at 37°C for 1·5 h, and the absorbance at 405 nm was measured. For the analysis of AFP molecular variants in serum samples, the following procedures were followed: PcAbcoated polystyrene beads were incubated with either 25 JlL of FUC-AFP-25 or FUC-AFP-75 in 175JlL of buffer A at 37°C for 1h to allow each AFP mixture to bind to solid phase PcAb. After washing with buffer A, these beads were incubated with 1 Jlg/mL of LCA for 1·5 h in buffer A, in order to allow this lectin to bind to a carbohydrate chain of the fucosylated AFP trapped by solid phase PcAb. The solid phase polystyrene beads for control experiments were not treated with LCA. The beads were then incubated with {j-D-galactosidase-Iabelled McAbl8H4 at 4°C for I h. The enzyme activity associated with the solid phase was determined by measuring the absorbance at 405 nm after incubation with p-nitrophenyl-p-D-galactopyranoside at 37°C for 1·5 h. Concentrations of AFP mixtures bound to the solid phase PcAb were expressed as the mean of triplicate determinations. Inhibition percentages of the binding of l8H4 to FUC-AFP-25 or FUC-AFP-75 were calculated by comparing with control experiments in which the LCA treatment was omitted.
In control experiments without LCA treatment, the PcAb-coated beads were allowed to react with each AFP mixture at various concentrations and the enzyme activity associated with beads was determined. Concentrations of AFP in the control experiments were calculated as the mean of triplicate determinations. Values represent the mean ± SD.
Serum samples from patients with AFP-100 producing hepatocellular carcinoma were examined in the same manner.
Preparation of the standard curve
The standard curve was constructed by plotting the absorbance values on the ordinate (arithmetic scale) against the concentration of FUC-AFP-25 or FUC-AFP-75 on the abscissa (logarithmic scale), and a computer programmed sigmoidal curve was applied in the present EIA method.
Reproducibility
The inter-assay reproducibility was assessed by repeated analysis of five samples in five consecutive assays. The calculated coefficients of variation (CV%) were 3·5 to 12·0% (mean = 7,2%). The intra-assay CVs of precision were 4·5-13·5% (mean = 6·0%, n = 10).
Statistical analysis
Statistical analyses were performed by using the unpaired t-test and chi-square test. Data are represented as mean ± SO. Concentration of FUC -AFP -75 (ng!mL-I ) (P < 0,01), 400 ngjmL (P < 0,05), 600 ngjmL (P < 0,01) and 800ngjmL (P < 0,01). Figure 4 shows that the LCA treatment of the FUC-AFP-75 trapped by solid phase PcAb gave 50% inhibition of binding of conjugate 18H4 to the AFP mixture compared with the controls. The differences in the mean % inhibition of the binding of 18H4 to FUC-AFP-75 between the experiments with and without LCA treatment were statistically significant at AFP concentrations of 100 ngjmL (P < 0·05), 200 ngjmL (P < 0'01), 400ngjmL (P < 0,01), 600ngjmL (P < 0,01) and 800 ngjmL (P < 0'001). Figure 5 shows a comparison of sets of data for FUC-AFP-25 and FUC-AFP-75. The differences in the mean percentage inhibition were statistically significant at total AFP concentrations of 100 ngjmL (P < 0,05), 200 ngjmL (P < 0,05), 600 ngjmL (P < 0'05) and 800 ngjmL (P < 0·0 I). At all five concentrations examined, the percentage inhibition with LCA treatment of the binding of conjugate 18H4 to FUC-AFP-25 and FUC-AFP-75 was statistically higher than that in each control system without the LCA treatment (P < 0·05 -P < 0,01, Fig. 3 and P < 0·05 -P < 0'001, Fig. 4, respectively) . In the case of non-fucosylated AFP, as previously described," there was little inhibition with LCA of the binding of conjugate 18H4 to the AFP molecular variant. At the five concentrations examined, the percentage inhibition with LCA of the binding of conjugate 18H4 to FUC-AFP-75 was higher than that of FUC-AFP-25, and at four out of five concentrations, the differences between FUC-AFP-75 and FUC-AFP-25 were statistically significant (P < 0·05 -P < 0'01, Fig. 5 ). Thus, by the present EIA system the AFP mixture which contained 25% fucosylated AFP was distinguishable, with statistical significance, from that which contained 75% fucosylated AFP. Next, 40 samples of serum from patients with hepatocellular carcinoma were analysed for AFP using this monoclonal EIA system, and then the data were compared with those obtained by conventional cross immuno-affinoelectrophoresis. The serum AFP concentrations of 40 patients with hepatocellular carcinoma ranged from 100 to 1270 ng/mL. When analysed· by cross immuno-affinoelectrophoresis the percentages of fucosylated AFP ranged from 0 to 100%. There was no significant trend in either the percentages of fucosylated AFP or in the concentrations of AFP in these 40 patients (Fig. 6 ).
RESULTS

Figure
As shown in Fig. 7 , there was a good correlation between the two sets of data obtained by the monoclonal EIA method and the conventional method over the range of fucosylated AFP percentages from 0 to 100% (P < 0'01, r = 0,79). For AFP concentrations of less than 400 ng(mL, there was also a positive correlation between these two sets of data ( Fig. 8) (P < 0·01, r = 0,78). A good agreement of the paired data obtained by the EIA method and by the conventional method was more clearly shown in the range over 17% offucosylated AFP, in which hepatocellular carcinoma was strongly suggested by the conventional method" (Fig. 9 ). Next, a chi-square test with 2 x 2 table was applied in the analyses of fucosylated AFP between the present EIA and the conventional method ( Table I) . Data of the present EIA were divided into two groups, depending on the percentage of fucosylated AFP. The first group shows percentages of less than 20% (a tentative demarcation value of fucosylated AFP between benign liver diseases and hepatocellular carcinomas) of binding inhibition of conjugate l8H4 to AFP trapped by solid phase. The second group shows greater than 20% of binding inhibition of the monoclonal conjugate. Data from the conventional electrophoresis were also divided into two groups. The first group shows percentages ofless than 17% of fucosylated AFP and the second shows percentages over 17%; a demarcation value between benign liver diseases and hepatocellular carcinomas in the conventional method as described previously." Thirtytwo (94%) of 34 sample sera were found to belong to the group in which inhibition percentages of McAbl8H4 to AFP trapped by solid phase were more than 20% by the present method, and 32 (87%) of 33 belonged to the group in which percentages of fucosylated AFP in serum sample was more than 17% by the conventional method. Five out of seven and five out of six were found to belong to the group in which percentages of fucosylated AFP included in samples were under the demarcation value. In this comparison, a statistically significant relationship was found between the present EIA and the conventional cross immunoaffinoelectrophoresis (P < 0'01, Table I ).
DISCUSSION
Several investigators have described the application of monoclonal antibody assay systems for the quantitative measurement of serum markers in patients with certain diseases. 17 -2o They claim that their methods are more specific than conventional ones and that they are more accurate in detection of diseases.
The degree of fucosylation of AFP has been revealed as a good marker for discrimination of hepatocellular carcinomas from nonmalignant liver diseases.l-" 7.9.16 The fucosylated and nonfucosylated molecular species of AFP have been identified by cross immuno-affinoelectrophoresis in the presence of LCA, by taking advantage of the affinity of the fucosylated species with this lectin. Similar methods have been used for diagnosis of neural tube defects 21 . 22 and liver diseases":" with lectins such as concanavalin A and LeA. However, the methods using crossed immuno-affinoelectrophoresis, imm uno blotting techniques and affinity chromatography are complicated and require technical skill. Therefore, we have aimed at providing a more convenient method which discriminates between the fucosylated and non-fucosylated molecular species of AFP for the detection of early stage of hepatocellular carcinoma.
In our previous study, we selected a monoclonal antibody 18H4 which might be suitable for such a clinical purpose. 13 The binding of 18H4 to the solid phase coated with fucosylated AFP was inhibited by pretreating the solid phase with LCA. However, such inhibition was not observed when the solid phase was coated with the non-fucosylated AFP. 13 In similar experiments with another reference monoclonal antibody, LCA exhibited little inhibition of the binding of the antibody to the solid phase coated with the fucosylated AFP. 13 As described above, McAbl8H4 was selected in the system with AFP-coated solid phase. Then we developed a model system for the analysis of serum samples of AFP molecular variants. PcAb-coated polystyrene beads were prepared and were incubated with fucosylated or nonfucosylated AFP at various concentrations from 200 to 2000 ng/rnl, in 3% BSA. Purified AFP molecular variants were distinguishable in this monoclonal EIA system in the presence of LCA. 13 The inhibition of the binding of l8H4 to fucosylated AFP can be reasonably explained by assuming that this monoclonal antibody recognizes an epitope of AFP which is closely located to the attachment site of a carbohydrate chain. Treatment with LCA of the fucosylated AFP would result in the binding of this lectin to its fucosylated sugar chain, and prevent 18H4 from binding to the AFP-molecular species by steric hindrance.
Here, we describe our new EIA and demonstrate its sensitivity and precision at lower concentrations of AFP and at lower percentages of fucosylated AFP. FUC-AFP-25 and FUC-AFP-75, mixtures of purified fucosylated and non-fucosylated AFP dissolved in normal human serum, could be discriminated with the present EIA method in the presence ofLCA at total AFP concentrations from 100 to 800 ng/ml, . These data suggest that the present EIA might be capable of distinction of AFP molecular variants at concentrations as low as 100 ng/ml, in sera of patients.
A clinical application of the present EIA was shown in sera from 40 patients with hepatocel-lular carcinoma at AFP concentrations from 100 to 1270 ng/ml, and at percentages of fucosylated AFP from 0 to 100% (Figs 6 and 7) . In this analysis, a good correlation was obtained between the present EIA method and the conventional method (Fig. 7) . At AFP concentrations of less than 400 ng/ml., the discriminatory power of the present EIA for AFP variants was also confirmed (Fig. 8) .
The chi-square test with 2 x 2 table was also performed to compare the data from the present EIA with those from conventional electrophoresis. The discriminant level selected for the present EIA was 20% of fucosylated AFP, and the two groups were divided at this level. In this 2 x 2 table for analysis of AFP molecular variants, there was a statistically significant relationship between the present EIA method and the conventional crossed immuno-affinoelectrophoresis (Table I) .
On the question of inhibition by more than 20% of the binding of conjugate 18H4 to fucosylated AFP by LCA, there was good agreement between the present EIA method and the electrophoretic technique ( Fig. 9 ). In a similar experiment using fucosylated AFP at less than 15%, there was not always a statistically significant different between controls with and without LCA treatment (data not shown). However, this was not clinically important because 17% of fucosylated AFP was considered as the cut-off point for discrimination of hepatocellular carcinoma from benign liver diseases, as previously described."
Thus, these results suggested that our new EIA with monoclonal antibody 18H4 would be useful for detection of an early stage of hepatocellular carcinoma.
